west
nile
viru
wnv
neurotrop
rna
viru
belong
flavivirida
famili
gener
transmit
human
infect
mosquito
bite
primarili
speci
howev
wnv
also
transmit
less
frequent
rout
includ
transfus
blood
blood
compon
organ
transplant
breastfeed
congenit
infect
infect
mosquito
bite
wnv
replic
keratinocyt
skinresidenti
dendrit
cell
langerhan
cell
latter
cell
carri
virus
drain
lymph
node
caus
viremia
subsequ
wnv
dissemin
peripher
organ
spleen
liver
possibl
spinal
cord
brain
human
wnv
infect
may
caus
injuri
death
neuron
variou
clinic
manifest
enceph
mening
flaccid
paralysi
persist
neurolog
sequela
possibl
death
particularli
elderli
immunocompromis
individu
wnv
strongli
activ
host
immun
respons
play
import
role
control
viremia
viral
dissemin
central
nervou
system
cn
recoveri
diseas
howev
mechan
wnv
pathogenesi
includ
tropism
neuron
cn
invas
viral
host
factor
contribut
imbal
viral
patholog
host
immun
still
remain
poorli
understood
although
wnv
first
discov
uganda
consid
minor
public
health
concern
first
appear
usa
sinc
dramat
spread
continent
state
usa
becam
endem
diseas
throughout
north
america
within
year
usa
alon
report
case
wnv
classifi
neuroinvas
claim
live
nearli
two
thousand
peopl
howev
actual
wnv
burden
like
much
higher
previous
thought
infect
individu
develop
clinic
wnv
diseas
estim
three
million
individu
infect
wnv
usa
symptomat
diseas
wnv
also
potenti
develop
unusu
clinic
manifest
may
involv
renal
diseas
myasthenia
gravi
myocard
suggest
rang
sever
wnv
diseas
may
even
wors
previous
believ
importantli
increas
number
wnv
outbreak
last
year
associ
greater
number
neuroinvas
case
higher
rate
fatal
howev
vaccin
antivir
therapeut
current
avail
limit
current
treatment
support
care
measur
intraven
fluid
antipyret
respiratori
support
prevent
secondari
infect
consid
worldwid
distribut
viru
evid
potenti
chang
pathogen
transmiss
urgent
need
develop
safe
effect
antivir
drug
vaccin
wnv
infect
intens
research
past
decad
made
signific
progress
design
develop
sever
treatment
prevent
method
wnv
infect
review
discuss
current
approach
recent
progress
toward
develop
vaccin
therapeut
antibodi
antivir
drug
wnv
infect
human
wnv
spheric
viru
nm
diamet
compris
icosahedr
nucleocapsid
surround
lipid
envelop
viru
contain
singlestrand
cap
plussens
rna
genom
approxim
kb
size
viral
genom
encod
polyprotein
precursor
undergo
posttransl
process
cellular
viral
proteas
gener
three
structur
protein
capsid
c
premembran
prm
envelop
e
seven
nonstructur
protein
structur
protein
form
virion
structur
wherea
nonstructur
protein
play
essenti
role
replic
viral
genom
assembl
virion
viral
pathogenesi
thu
structur
nonstructur
protein
wnv
may
potenti
target
develop
vaccin
antivir
therapeut
tabl
wnv
virion
structur
c
protein
encapsul
viral
genom
rna
form
nucleocapsid
envelop
lipid
bilay
trimmer
prme
heterodim
form
spikelik
project
among
structur
protein
e
protein
mediat
crucial
role
bind
cellular
receptor
membran
fusion
entri
wnv
host
cell
make
key
target
develop
vaccin
neutral
antibodi
entri
inhibitor
crystal
structur
analysi
confirm
e
protein
fold
three
structur
distinct
ectodomain
ed
term
edi
edii
ediii
among
ediii
consist
major
neutral
epitop
antigen
choic
elicit
product
neutral
antibodi
base
structur
character
antiflavivir
monoclon
antibodi
human
nonhuman
primat
appear
epitop
flavivir
e
protein
complex
divers
previous
thought
addit
map
bcell
tcell
epitop
led
identif
mani
immunodomin
epitop
structur
nonstructur
protein
wnv
among
nonstructur
protein
bestcharacter
multifunct
protein
contain
enzymat
activ
essenti
viral
replic
enzymat
function
receiv
consider
attent
potenti
target
antivir
drug
develop
protein
contain
two
distinct
function
domain
ntermin
domain
amino
acid
residu
serin
proteas
activ
requir
polypeptid
cofactor
activ
recent
xray
crystallograph
studi
shown
conform
control
substrat
bind
proteas
contrast
ctermin
domain
function
rna
helicas
nucleosid
triphosphatas
rna
triphosphatas
although
atpas
helicas
activ
function
independ
protein
suggest
regul
activ
besid
role
cleav
viral
protein
proteas
activ
may
also
contribut
host
cell
apoptosi
neuropathogenesi
cleav
host
protein
similarli
anoth
multifunct
protein
contain
ntermin
methyltransferaseguanyltransferas
ctermin
rnadepend
rna
polymeras
rdrp
activ
ntermin
methyltransferas
guanylyltransferas
activ
essenti
format
cap
structur
viral
mrna
thu
function
crucial
protect
viral
genom
effici
translat
viral
polyprotein
ntermin
domain
contain
multipl
residu
phosphoryl
host
protein
kinas
besid
function
viral
replic
also
play
role
viral
pathogenesi
antagon
host
interferon
respons
nonstructur
protein
form
scaffold
viral
replic
complex
also
role
replic
viral
genom
host
immun
evas
mutat
protein
may
attenu
wnv
flavivirus
addit
recent
success
clinic
trial
hepat
c
viru
inhibitor
suggest
target
nonstructur
protein
may
ideal
strategi
develop
therapeut
flavivirus
includ
wnv
develop
aneffect
vaccin
requir
multipl
step
design
develop
rigor
evalu
safeti
efficaci
fig
sinc
biolog
vaccineinduc
immun
principl
vaccin
develop
test
extens
discuss
discuss
topic
immun
laboratori
anim
subsequ
challeng
anim
pathogen
control
condit
common
method
earli
evalu
vaccin
effect
variou
factor
rout
administr
immunogen
dose
type
adjuv
greatli
influenc
effect
vaccin
candid
mous
model
wnv
infect
partial
mimic
clinic
cours
wnv
diseas
human
help
understand
wnv
pathogenesi
also
facilit
develop
test
wnv
vaccin
anim
studi
vaccin
efficaci
infect
anim
observ
mortal
monitor
surviv
patholog
seroconvers
immun
respons
vaccin
safeti
plaqu
reduct
neutral
test
pnrt
gold
standard
method
assess
whether
candid
wnv
vaccin
induc
neutral
antibodi
anim
human
standard
guidelin
method
avail
neutral
antibodi
titer
correl
protect
diseas
licens
flaviviru
vaccin
consid
key
marker
assess
vaccin
efficaci
exampl
protect
threshold
japanes
enceph
viru
vaccin
correl
titer
neutral
antibodi
serum
consid
protect
although
wnv
lineag
strain
commonli
involv
human
diseas
use
vaccin
efficaci
test
recent
emerg
pathogen
lineag
strain
europ
rais
addit
concern
wnv
vaccin
efficaci
studi
wnv
vaccin
candid
base
lineag
strain
may
protect
lineag
strain
promis
result
anim
studi
human
wnv
vaccin
evalu
term
protect
natur
challeng
well
safeti
immunogen
seri
clinic
trial
phase
tradit
modern
approach
use
develop
wnv
vaccin
common
approach
list
base
vaccin
use
power
modern
genet
tool
viral
protein
express
suitabl
vector
develop
dna
vaccin
wnv
infect
howev
strategi
sometim
hamper
poor
immunogen
potenti
safeti
concern
integr
foreign
dna
host
genom
chimericrecombin
vaccin
approach
reli
replac
gene
establish
viral
vaccin
strain
equival
wnv
gene
sever
live
attenu
vaccin
viral
vector
may
use
backbon
develop
recombin
wnv
vaccin
candid
yellow
fever
viru
yfv
vaccin
attenu
denv
serotyp
hivbas
lentiviru
vector
vaccin
schwarz
strain
attenu
measl
viru
vesicular
stomat
viru
vsv
vaccin
vector
adenoviru
liveattenu
vaccin
attenu
wnv
achiev
classic
cell
cultur
passag
anim
passag
andtarget
genet
mutat
howev
sever
potenti
challeng
includ
residu
pathogen
revers
virul
strain
rel
short
selflif
demand
safe
biolog
product
system
need
overcom
inactiv
kill
chemic
inactiv
live
virus
may
use
develop
inactiv
kill
viru
particl
limit
possibl
incomplet
inactiv
shortliv
immun
requir
multipl
dose
effici
immun
subunit
recombin
protein
vaccin
approach
use
solubl
recombin
protein
protein
express
viruslik
particl
vlp
platform
vaccin
candid
success
approach
reli
optimum
immunogen
vaccin
protein
vaccin
gener
requir
multipl
boost
strong
adjuv
provid
accept
efficaci
west
nile
dna
first
licens
dna
vaccin
veterinari
use
follow
success
demonstr
vaccin
induc
b
cellbas
immun
immun
mice
hors
dna
vaccin
express
prm
e
gene
wnv
domain
iii
diii
region
e
gene
approachha
wide
use
develop
variou
dna
vaccin
wnv
one
first
dna
vaccin
introduc
phase
clinic
trial
base
circular
plasmid
dna
vector
incorpor
cytomegaloviru
cmv
promot
express
prm
e
code
sequenc
downstream
modifi
jev
signal
sequenc
although
seriou
advers
effect
report
low
immunogen
hamper
develop
effort
improv
immunogen
vaccin
addit
regulatori
element
human
tcell
leukemia
viru
type
incorpor
conjunct
previous
use
cmv
promot
without
signific
success
test
clinic
trial
sever
studi
also
test
carrierconjug
differ
inocul
rout
improv
immunogen
effici
deliveri
dna
vaccin
exampl
dna
vaccin
express
full
length
truncat
wnv
e
gene
deriv
conjug
region
complement
protein
induc
strong
igg
titer
effici
protect
mice
vaccin
gene
gun
method
anoth
studi
plasmid
dna
vector
express
ectodomain
wnv
e
protein
linear
polyethyleneimin
lpei
nanoparticl
coval
bound
mannos
develop
howev
conjug
fail
gener
suffici
eprotein
specif
humor
respons
despit
boost
vaccin
mice
recombin
e
protein
induc
signific
increas
neutral
antibodi
larg
delet
capsid
gene
flavivir
rna
result
failur
produc
infecti
virion
retain
abil
replic
viral
rna
genom
express
prm
e
protein
novel
properti
use
develop
sever
plasmid
dna
pdna
vector
transfect
produc
singleround
infecti
particl
srip
turn
produc
viruslik
particl
vlp
contain
viral
surfac
protein
without
viral
genom
strategi
use
develop
sever
candid
dna
vaccin
flaviviru
express
e
prm
protein
plasmid
vector
form
vlp
use
approach
sever
plasmiddna
construct
develop
candid
dna
vaccin
wnv
type
dna
vaccin
encod
singleround
infecti
particl
express
eprm
fulllength
cdna
copi
attenu
wnv
kunjin
strain
ectodomain
e
protein
cell
cultur
animalpassag
use
convent
method
develop
liveattenu
vaccin
advent
genet
manipul
techniqu
make
feasibl
introduc
target
mutat
viral
genom
attenu
virus
use
approach
wnv
vaccin
replivax
wn
develop
intern
delet
region
capsid
gene
shown
induc
neutral
antibodi
protect
immun
respons
mice
hamster
nonhuman
primat
replivax
wn
strongli
activ
b
cell
popul
secret
igg
antibodi
induc
prolong
activ
memori
specif
plasma
cell
innat
immun
signal
pathway
signal
pathway
involv
strong
activ
b
cell
respons
develop
germin
center
gener
longliv
plasma
cell
product
antibodi
follow
immun
relpivax
wn
vaccin
addit
anoth
live
attenu
wnv
vaccin
develop
gener
mutat
glycosyl
site
e
protein
induc
neutral
antibodi
protect
immun
respons
mice
similarli
approach
introduct
mutat
e
gene
previous
character
attenu
also
use
develop
attenu
wnv
vaccin
candid
use
approach
recombin
live
attenu
wnv
vaccin
veterinari
use
develop
licens
merial
recombitek
vaccin
express
wnv
prm
e
protein
canarypox
viru
backbon
use
similar
approach
chimer
vaccin
develop
replac
prm
e
gene
yfv
vaccin
strain
prm
e
gene
first
recombin
wnv
vaccin
candid
test
clinic
trial
introduct
three
mutat
respons
attenu
jev
equival
posit
wnv
e
gene
attenu
similarli
vaccin
candid
attenu
delet
untransl
region
utr
viral
genom
engin
express
prm
e
preclin
evalu
mice
gees
monkey
show
strong
immunogen
clinic
trial
addit
chimer
vaccin
candid
express
wnv
prm
e
protein
shown
protect
mice
infect
wnv
strain
anoth
recombin
wnv
vaccin
base
influenza
vaccin
flunadiii
develop
clone
diii
wnv
e
ntermin
region
neuraminidas
influenza
viru
vaccin
candid
induc
wnvspecif
neutral
igg
protect
mice
lethal
wnv
infect
similarli
recombin
adenovir
vaccin
vector
cadvaxwnvii
express
three
structur
protein
c
prm
e
along
wnv
induc
neutral
antibodi
mice
sever
recombin
wnv
vaccin
also
develop
express
wnv
protein
backbon
attenu
measl
viru
vesicular
stomat
viru
herp
commonapproach
develop
nonrepl
inactiv
viral
vaccin
inactiv
entir
viru
particl
use
chemic
formalininactiv
wnv
vaccin
base
strain
first
success
veterinari
vaccin
market
pfizer
west
nile
licens
anoth
veterinari
wnv
vaccin
use
kill
viru
also
licens
usda
market
boehring
ingelheim
wnv
recent
inactiv
wnv
vaccin
wnvax
base
wnv
protect
mice
lethal
wnv
infect
exhibit
immunogen
monkey
addit
wnv
formalin
inactiv
wnv
strain
induc
neutral
antibodi
protect
immun
gees
altern
tradit
formalinbas
vaccin
novel
hydrogen
peroxid
inactiv
approach
recent
use
produc
wholeviru
vaccin
wnv
mice
immun
wnv
vaccin
candid
develop
high
serum
neutral
titer
offer
complet
protect
vaccin
mice
lethal
wnv
challeng
one
inactiv
vaccin
recent
introduc
phase
clinic
trial
although
inactiv
virul
wnv
viru
strain
success
achiev
chemicalinactiv
method
use
natur
attenu
kunjin
strain
wnv
chemic
synthes
viru
cdna
system
start
materi
also
propos
sever
studi
demonstr
solubl
recombin
protein
vlp
base
approach
could
serv
develop
wnv
vaccin
vlp
special
subvir
particl
lack
viral
genom
sole
contain
viral
structur
protein
express
viral
protein
envelop
membran
differ
vector
product
system
evalu
develop
variou
subunit
vaccin
wnv
exampl
recombin
truncat
form
wnv
e
protein
produc
escherichia
coli
induc
neutral
antibodi
protect
mice
lethal
wnv
challeng
addit
recombin
truncat
wnv
e
protein
produc
sf
insect
cell
via
baculoviru
infect
induc
neutral
antibodi
protect
mice
hamster
wnv
infect
recombin
baculoviru
also
use
express
wnv
prm
e
protein
mammalian
cell
cmv
promot
without
vesicular
stomat
viru
glycoprotein
bacgprm
vaccin
induc
robust
immun
respons
inocul
mice
produc
neutral
antibodi
inflammatori
cytokin
recent
propos
novel
approach
known
pseudotyp
retroviru
gag
polyprotein
form
vlp
scaffold
display
ectodomain
human
membran
glycoprotein
fuse
high
affin
ige
receptor
gamma
chain
rige
use
retroviru
base
vlp
platform
wnv
vaccin
gener
replac
ectodomain
glycoprotein
ediii
wnv
induc
neutral
antibodi
mice
recombin
e
protein
produc
drosophila
cell
develop
hawaii
biotech
wnv
subunit
vaccin
candid
test
phase
clinic
trial
although
preclin
studi
reveal
wnvspecif
neutral
antibodi
respons
vaccin
anim
immunogen
vaccin
human
low
increas
immunogen
conjug
recombin
protein
nanoparticl
pathogen
associ
molecular
pattern
pamp
carrieradjuv
test
instanc
recombin
wnv
e
protein
administ
unmethyl
cpg
oligonucleotid
adjuv
load
onto
cpgmodifi
nanoparticl
strongli
activ
dendrit
cell
lymphocyt
elicit
immun
respons
produc
high
titer
immun
mice
similarli
mice
inject
diii
wnv
e
conjug
bacteri
flagellin
vlp
deriv
bacteriophag
engin
express
diii
wnv
e
also
significantli
increas
neutral
antibodi
product
protect
immun
mice
despit
intens
effort
develop
wnv
vaccin
reach
clinic
trial
stage
clinic
trial
candid
vaccin
fail
demonstr
effici
immun
safeti
develop
new
tool
antigen
screen
expand
understand
immunolog
correl
vaccin
inducedimmun
discoveri
novel
adjuv
vaccin
deliveri
may
facilit
design
develop
wnv
vaccin
exampl
knowledg
genom
inform
bioinformat
use
silico
identif
candid
antigen
develop
vaccin
novel
method
call
revers
vaccinolog
comprehens
tool
quickli
identifi
potenti
antigen
code
genom
may
use
develop
novel
viral
vaccin
develop
vaccin
group
b
streptococci
prove
potenti
approach
similarli
structur
approach
improv
antigen
vaccin
ration
design
develop
util
knowledg
immunolog
structur
biolog
bioinformat
addit
increas
understand
immunogenet
role
environment
host
factor
determin
variat
vaccin
immun
may
offer
new
approach
design
effect
vaccin
wnv
infect
human
therapeut
monoclon
antibodi
mab
hyperimmun
sera
success
use
prophylaxi
number
infecti
noninfecti
diseas
includ
wnv
infect
recent
year
number
mab
preclin
develop
clinic
trial
increas
significantli
far
nearli
mab
approv
therapeut
us
fda
includ
human
mab
synagi
palivizumab
prevent
use
respiratori
syncyti
viru
rsv
infect
neonat
immunocompromis
individu
mani
mab
develop
virus
sarscov
influenza
emerg
virus
includ
wnv
show
excel
therapeut
potenti
clinic
use
human
wnv
infect
induc
potent
humor
immun
respons
essenti
control
viremia
limit
wnv
dissemin
cn
hyperimmun
sera
affinitypurifi
antibodi
harvest
wnvinfect
human
anim
protect
wildtyp
immunocompromis
micefrom
wnv
challeng
laboratori
condit
addit
wnv
patient
receiv
antibodi
wnv
seroposit
donor
recov
wnv
infect
studi
encourag
effort
toward
develop
human
human
monoclon
antibodi
wnv
also
led
discoveri
sever
potent
monoclon
antibodi
show
effici
protect
mice
hamster
wnv
infect
among
human
antiwnv
mab
bind
highli
conserv
epitop
wnv
e
protein
block
viral
fusion
provid
postexposur
therapeut
potenti
antibodi
current
assess
potenti
use
wnv
therapeut
antibodi
phase
clinic
trial
show
anoth
human
recombin
antibodi
target
e
protein
wnv
known
good
safeti
toler
profil
healthi
human
howev
phase
ii
trial
assess
efficaci
wnv
infect
fail
due
poor
enrol
particip
besid
develop
whole
antibodi
recombin
fusion
protein
also
gener
singlechain
antibodi
fragment
variabl
region
antibodi
fragment
target
e
protein
may
potenti
candid
immunoprophylaxi
therapi
wnv
infect
recombin
human
singlechain
variabl
region
antibodi
fragment
fvfc
fusion
protein
protect
role
wnv
infect
mice
one
potenti
limit
approach
antibodydepend
enhanc
ade
phenomenon
infect
virus
enhanc
virusreact
antibodi
result
effici
viru
entri
fc
receptormedi
pathway
phenomenon
play
role
patholog
sever
dengu
infect
also
observ
wnv
vitro
although
role
ade
wnv
diseas
unclear
develop
therapeut
antibodi
wnv
address
potenti
issu
anoth
limit
antibodybas
therapeut
high
product
cost
limit
mab
scalabl
produc
therapeut
protein
includ
antibodi
plant
may
promis
solut
feasibl
approach
affirm
success
product
antiwnv
monoclon
antibodi
plant
nicotiana
benthamiana
plantderiv
confer
potent
neutral
activ
vitro
without
ade
effici
bind
complement
fc
receptor
protect
mice
lethal
wnv
challeng
similar
potenc
mammaliancel
counterpart
antibodi
employsever
mechan
control
wnv
viral
infect
includ
blockag
viral
entri
fcdepend
viral
clearanc
complementmedi
viral
lysi
antibodydepend
cytotox
infect
cell
current
research
develop
therapeut
antibodi
wnv
design
test
effici
neutral
potenti
increas
understand
biolog
antibodi
fc
region
particular
role
glycan
fc
mediat
function
may
facilit
design
develop
highqual
antibodi
glycoengin
engin
antibodi
fc
region
may
use
overcom
ade
modul
pharmacokinet
enhanc
fc
mediat
effector
function
enhanc
antibodydepend
cell
mediat
cytotox
adcc
complement
bind
phagocytosi
recent
technolog
advanc
develop
product
purif
also
eas
achiev
desir
qualiti
efficaci
safeti
requir
fda
approv
make
monoclon
antibodi
promis
therapeut
option
thu
monoclon
antibodi
may
prove
use
wnv
prophylaxi
therapi
particularli
elderli
immunocompromis
individu
limit
abil
respond
vaccin
meet
therapeut
goal
controlledclin
trial
therapeut
antibodi
ensur
prophylact
therapeut
efficaci
along
optim
dose
time
administr
across
rang
patient
group
develop
antivir
drug
multistep
process
take
year
reach
market
gener
overview
drug
develop
process
outlin
fig
hittolead
initi
stage
drug
discoveri
small
molecul
hit
screen
evalu
identifi
promis
lead
compound
therapeut
potenti
recent
progress
develop
multipl
approach
design
screen
identif
valid
hit
compound
review
wit
grow
interest
field
drug
develop
signific
progress
structur
function
character
structur
nonstructur
protein
wnv
flavivirus
facilit
identif
therapeut
target
hittolead
screen
exampl
character
pseudoatom
structur
matur
immatur
wnv
atom
resolut
structur
wnv
flavivir
protein
xray
crystallographi
nuclear
magnet
reson
nmr
spectroscopi
structur
character
bind
neutral
monoclon
antibodi
e
protein
wnv
greatli
increas
understand
structur
function
aspect
potenti
therapeut
target
two
approach
commonli
use
small
molecul
inhibitor
screen
includ
targetbas
approach
cellbas
approach
targetbas
screen
sever
method
appli
includ
enzym
activitybas
screen
fragmentbas
screen
affinitybas
screen
structurebas
ration
design
silico
dock
contrast
cellbas
approach
use
viral
infect
replicationdepend
assay
identifi
inhibitor
approach
present
uniqu
set
merit
challeng
instanc
gener
difficult
identifi
target
also
achiev
specif
cellbas
assay
identifi
inhibitor
may
potenti
affect
multipl
step
viral
infect
cycl
may
target
viral
host
protein
although
inhibitor
identifi
cellbas
assay
may
prove
use
antivir
drug
candid
compound
could
also
act
nonspecif
thu
elucid
mechan
action
requir
targetbas
approach
highli
effici
screen
process
howev
inhibitor
screen
method
may
requir
modif
effect
cellular
permeabl
valid
antivir
activ
select
toxic
use
cellbas
assay
final
stage
lead
compound
select
vitro
vivo
pharmacokinet
profil
includ
efficaci
plasma
stabil
halflif
exposur
bioavail
preclin
toxic
plan
clinic
trial
e
protein
wnv
flavivirus
play
key
role
viral
entri
host
cell
mediat
viral
attach
host
cell
receptor
subsequ
membran
fusion
bind
host
cell
receptor
wnv
enter
cell
clathrinindepend
endocytosi
process
follow
lowphdepend
viral
uncoat
endosom
releas
viral
genom
cytoplasm
replic
inhibitor
disrupt
interact
e
protein
cell
receptor
inhibit
membran
fusion
would
potenti
antivir
wnv
two
success
hiv
drug
maraviroc
antagonist
enfuvirtid
peptid
inhibitor
respect
block
viral
entri
membran
fusion
attest
antivir
strategi
flavivir
e
glycoprotein
contain
sever
function
site
hydrophob
pocket
receptorbind
domain
stem
domain
may
target
inhibitor
among
hydrophob
ligandbind
pocket
hing
region
domain
ii
e
protein
play
import
role
lowphmedi
membran
fusion
process
uniqu
target
develop
smallmolecul
inhibitor
flavivirus
variou
screen
approach
use
identifi
inhibitor
denv
flavivirus
bind
hydrophob
pocket
interfer
conform
chang
e
protein
inhibitor
design
test
denv
report
exhibit
antivir
activ
wnv
howev
compound
fail
drug
develop
due
undesir
properti
low
solubl
cytotox
domain
iii
e
glycoprotein
mediat
receptorbind
potenti
target
develop
inhibitor
disrupt
viral
attach
host
cell
receptor
neutral
antibodi
e
protein
proven
potenti
strategi
sever
compound
also
shown
interfer
bind
flavivirus
host
cell
receptor
howev
lack
understand
cell
receptor
wnv
hamper
success
approach
identif
cellular
receptor
wnv
understand
interact
may
provid
new
opportun
identifi
small
molecul
inhibitor
interrupt
bind
wnv
host
cell
receptor
viral
proteas
essenti
wnv
life
cycl
cleav
viral
polyprotein
precursor
function
protein
success
develop
licens
proteas
inhibitor
hcv
provid
proof
concept
feasibl
similar
target
proteas
virus
ntermin
domain
flavivir
amino
acid
serin
proteas
activ
wherea
hydrophob
region
protein
serv
cofactor
activ
enzymat
activ
proteas
wnv
process
viral
polyprotein
precursor
structur
nonstructur
protein
disrupt
activ
lethal
wnv
addit
wnv
proteas
also
cleav
host
protein
may
contribut
neuropathogenesi
recent
progress
express
stabl
identif
highaffin
substrat
viral
enzym
promot
largescal
screen
proteas
inhibitor
wnv
flavivirus
wide
rang
assay
convent
enzymesubstr
base
detect
hplc
elisa
highthroughput
fluorescencebas
detect
method
develop
screen
viral
proteas
inhibitor
thu
proteas
attract
target
develop
antivir
wnv
flavivirus
review
except
aprotinin
apancreat
trypsin
inhibitor
classic
inhibitor
serin
proteas
inhibit
flavivir
proteas
activ
although
aprotinin
potent
inhibitor
flavivir
proteas
compound
withdrawn
market
due
safeti
issu
screen
identifi
small
molecul
inhibitor
flaviviru
proteas
high
throughput
screen
structurebas
drug
design
use
strategi
base
identif
alloster
inhibitor
target
interfac
proteas
activ
site
proteas
former
strategi
may
overcom
nonspecif
latter
due
larg
conserv
activ
site
human
viral
serin
proteinas
number
inhibitor
wnv
proteas
identifi
silico
dock
highthroughput
screen
use
vitro
enzym
activitybas
assay
howev
compound
fail
demonstr
potent
antivir
activ
cell
cultur
although
compound
identifi
approach
show
antiwnv
activ
cellbas
assay
none
inhibitor
progress
beyond
hit
optim
stage
discoveri
proteas
inhibitor
hamper
larg
due
difficulti
obtain
cocryst
structur
inhibitorproteas
complex
moreov
weak
bind
affin
activ
site
due
flat
charg
natur
design
potent
small
molecul
inhibitor
structurebas
method
becom
difficult
helicas
enzym
unwind
nucleic
acidbi
use
energi
deriv
hydrolysi
ntp
ctermin
domain
wnv
contain
helicasenucleas
activ
play
import
role
virul
pathogenesi
high
throughput
assay
measur
helicas
activ
monitor
helicasecatalyz
strand
separ
realtim
use
radioact
fluorescentlabel
oligonucleotid
develop
screen
helicas
inhibitor
sever
small
molecul
inhibitor
target
helicas
hcv
develop
use
substratebas
assay
compound
identifi
evalu
vitro
ntpaseshelicas
wnv
flavivirus
howev
inhibitori
effect
wnv
helicas
compound
specif
either
dna
rna
substrat
exampl
compound
name
tbbt
halogen
benzotriazol
inhibit
helicas
ntpase
activ
seri
ringexpand
nucleosidenucleotid
analog
ren
also
inhibit
ntpaseshelicas
activ
flavivirus
includ
wnv
hcv
jev
howev
compound
show
promis
antiwnv
activ
cell
cultur
nucleosid
analog
imidazo
pyridazin
nucleosid
broad
spectrum
antiparasit
drug
name
ivermectin
inhibit
helicas
also
show
antiwnv
activ
cell
cultur
rnadepend
rna
polymeras
rdrp
activ
ctermin
protein
wnv
flavivirus
attract
target
develop
antivir
agent
two
approach
use
target
wnv
rdrp
includ
nucleosid
inhibitor
ni
nonnucleosid
inhibitor
nni
ni
also
known
type
inhibitor
nucleosidenucleotid
analog
target
activ
site
polymeras
gener
compet
natur
ntp
substrat
rdrp
block
incorpor
viral
genom
replic
lead
incomplet
replic
mutat
viral
genom
success
ni
sever
virus
includ
herpesvirus
hbv
hcv
alreadi
prove
therapeut
potenti
class
compound
addit
ni
gener
display
broadspectrum
antivir
activ
across
relat
rna
virus
suggest
potenti
panflavivir
therapeut
variou
cellbas
cellfre
assay
develop
highthroughput
screen
flavivir
rdrp
inhibitor
far
sever
ni
inhibit
wnv
denv
rna
virus
identifi
exampl
favipiravir
relat
compound
select
inhibit
viral
rnadepend
rna
polymeras
potent
antiinfluenza
activ
antivir
drug
current
evalu
clinic
trial
influenza
viru
addit
favipiravir
also
block
replic
mani
rna
virus
includ
wnv
promis
drug
candid
broad
rang
rna
viral
diseas
two
nucleosid
analog
call
deriv
triphosph
adenosin
respect
also
broadspectrum
antivir
compound
target
viral
rdrp
inhibit
denv
hcv
wnv
similarli
two
ni
inhibitor
triphosph
inhibit
four
denv
serotyp
wnv
contrast
ni
inhibitor
antivir
nni
inhibitor
also
known
type
inhibitor
interfer
function
viral
polymeras
occupi
alloster
site
thu
prevent
viral
rna
synthesi
analysi
rdrp
crystal
structur
wnv
reveal
caviti
play
critic
role
viral
replic
suggest
potenti
target
screen
structurebas
alloster
inhibitor
nsulfonylanthranil
acid
deriv
identifi
highthroughput
screen
exampl
alloster
inhibitor
rdrp
activ
denv
howev
compound
specif
denv
show
activ
wnv
rdrp
recent
studi
demonstr
conform
chang
occur
polymeras
bind
inhibitor
howev
similar
antivir
activ
nni
inhibitor
target
polymeras
wnv
report
yet
messeng
rna
mrna
wnv
possess
cap
play
import
role
stabil
mrna
translat
methyltransferas
mtase
activ
ntermin
domain
respons
methyl
viral
rna
cap
addit
mtaseact
also
respons
evad
host
antivir
interferon
respons
play
import
role
wnv
pathogenesi
sever
structur
function
studi
along
identif
sever
potenti
inhibitor
suggest
target
mtase
repres
novel
approach
develop
novel
therapeut
wnv
flavivirus
flavivirus
mtase
catalyz
sequenti
methyl
viral
rna
cap
use
sadenosyllmethionin
sam
methyl
donor
contain
singl
bind
site
sam
crystal
structur
addit
mtase
activ
bind
gtp
shown
mtase
domain
sever
member
flaviviru
sever
assay
develop
highthroughput
screen
methyltransferas
inhibitor
structuralbas
ligandbas
method
ration
design
sam
analog
identifi
sever
inhibitor
target
mtase
activ
denv
wnv
nonspecif
inhibit
host
mtase
one
potenti
drawback
sam
analog
specif
inhibit
flavivir
host
mtase
achiev
target
pocket
near
sambind
site
two
nucleosid
analog
identifi
potent
inhibit
mtase
wnv
without
inhibit
human
mtase
one
compound
show
antivir
activ
wnv
cell
cultur
addit
sever
screen
studi
yfv
denv
identifi
hit
target
mtase
activ
show
antivir
activ
wnv
cell
cultur
howev
extens
multistag
molecular
dock
approach
screen
librari
million
commerci
compound
two
activ
site
denv
mtasegtas
fail
identifi
specif
hit
recent
nucleosid
scaffold
deriv
azt
demonstr
antivir
activ
wnv
denv
bind
mtase
sever
potenti
tool
includ
ration
design
phase
display
librari
develop
highthroughput
screen
specif
antivir
peptid
enfuvirtid
peptid
base
stem
region
hiv
exemplifi
effici
antivir
peptid
current
clinic
use
thu
antivir
peptid
may
serv
novel
therapeut
measur
wnv
sever
antivir
peptid
target
structur
nonstructur
protein
wnv
flaviviru
identifi
target
wnv
e
protein
antivir
peptid
potenti
strategi
block
viru
attach
entri
host
cell
sever
short
antivir
peptid
amino
acid
residu
bind
wnv
e
protein
identifi
screen
murin
brain
cdna
phage
display
librari
one
peptid
reduc
viremia
fatal
wnv
infect
mice
effici
penetr
murin
barrier
impli
may
antivir
activ
cn
similarli
peptid
inhibitor
target
domain
ii
wnv
e
protein
design
use
physicochem
algorithm
approach
potent
inhibit
wnv
infect
anoth
peptid
design
target
domain
ii
denv
e
show
antivir
activ
denv
wnv
addit
ration
drug
design
approach
use
identifi
peptidomimet
mimic
proteas
substrat
inhibit
activ
mechan
propos
peptidomimet
cleav
peptid
substrat
consist
basic
amino
acid
arg
ly
sidechain
amino
acid
gli
ser
ala
thu
prefer
peptid
substrat
contain
sever
posit
charg
amino
acid
common
method
screen
peptid
inhibitor
proteas
employ
fluorophor
conjug
peptid
substrat
contain
basic
amino
acid
posit
cleavag
peptid
substrat
proteas
result
releas
fluorophor
increas
fluoresc
sever
peptid
inhibitor
proteas
identifi
wnv
novel
agmatin
dipeptid
inhibitor
improv
inhibitori
activ
wnv
recent
identifi
addit
recombin
peptid
call
shown
inhibit
proteas
howev
peptid
show
poor
activ
cellbas
assay
test
vivo
efficaci
thu
peptid
inhibitor
proteas
identifi
far
fail
earli
develop
stage
potenti
limit
approach
includ
poor
pharmacokinet
properti
due
charg
natur
peptid
lack
specif
requir
intraven
deliveri
rapid
degrad
plasma
costli
product
rna
interfer
rnai
cellular
process
first
describ
nematod
caenorhabd
elegan
process
specif
degrad
rna
sequencespecif
manner
conserv
mammalian
cell
rnai
natur
defens
eukaryot
cell
viral
infect
may
promis
strategi
develop
potenti
antivir
therapeut
numer
sirna
target
identifi
genom
region
wnv
encod
structur
nonstructur
protein
sirna
target
protein
effect
inhibit
wnv
replic
besid
sirna
target
code
region
sirna
target
noncod
region
also
identifi
inhibit
wnv
replic
sequencespecif
manner
although
antiwnv
sirna
effici
block
viral
replic
cell
cultur
similar
success
difficult
achiev
anim
model
quick
degrad
serum
nucleas
failur
reach
target
cell
rapid
renal
excret
due
small
size
anion
charact
hinder
clinic
applic
antivir
sirna
sever
deliveri
system
includ
cellpenetr
peptid
nanoparticl
viral
vector
may
improv
sirna
stabil
enhanc
deliveri
effici
despit
mani
challeng
use
antivir
sirna
antiwnv
therapeut
remain
promis
cytokin
signal
control
divers
immun
function
infect
autoimmun
diseas
cancer
variou
immunomodulatori
immunostimulatori
cytokin
chemokin
identifi
play
protect
patholog
role
wnv
infect
exampl
typei
interferon
ifn
interleukin
il
macrophag
migrat
inhibitori
factor
mif
protect
wnv
infect
wherea
favor
wnv
pathogen
pharmacolog
blockad
neutral
antibodi
shown
protect
mice
wnv
challeng
type
ifn
inhibit
mani
flavivirus
includ
wnv
use
therapeut
hepat
c
viru
although
therapeut
effect
type
ifn
wnv
yet
evalu
applic
may
limit
due
antagonist
role
wnv
protein
ifn
signal
interestingli
treatment
pegyl
also
known
type
iii
interferon
recent
shown
protect
mice
lethal
wnv
infectionbi
decreas
barrier
permeabl
thu
strategi
target
express
cytokin
chemokin
block
signal
direct
use
recombin
cytokin
may
novel
approach
treat
wnv
infect
control
patholog
virus
util
host
cellular
system
entri
genom
replic
transcript
synthesi
viral
protein
product
viral
progeni
addit
interact
viral
protein
cellular
protein
may
evad
host
immun
defens
favor
viral
replic
pathogenesi
sever
host
pathway
enzym
includ
clathrinmedi
endocytosi
cyclophilin
ubiquitinproteasom
system
unfold
protein
respons
nucleotid
biosynthesi
posttransl
protein
modif
lipid
metabol
suggest
flaviviru
replic
pathogenesi
target
host
factor
may
use
strategi
develop
antivir
therapeut
flavivirus
includ
wnv
infect
far
mani
inhibitor
target
host
protein
develop
test
wnv
flavivirus
hcv
host
cyclophilin
famili
cellular
peptidylprolyl
isomeras
may
serv
compon
flaviviru
replic
complex
play
role
flavivir
replic
target
enzym
cyclosporin
inhibit
replic
wnv
target
lipid
signal
metabol
bioactiv
lipid
signal
modul
retinamid
fenretinid
also
inhibit
replic
wnv
flavivirus
similarli
ribavirin
mycophenol
acid
target
inosin
monophosph
dehydrogenas
impdh
enzym
purin
biosynthesi
therebi
inhibit
replic
flavivirus
addit
brequinar
block
pyrimidin
biosynthesi
also
inhibit
replic
broad
rang
rna
virus
includ
wnv
flavivirus
besid
block
viral
genom
replic
antivir
target
ofoth
step
asviru
matur
assembl
viral
dissemin
brain
also
suggest
test
wnv
instanc
inhibitor
alphaglucosidas
ii
enzym
play
role
process
nlink
oligosaccharid
viral
glycoprotein
also
inhibit
wnv
flavivirus
although
mechan
wnv
enter
brain
still
poorli
understood
two
potenti
rout
includ
axon
retrograd
transport
art
peripher
nervou
system
direct
hematogen
diffus
via
breakdown
plexu
barrier
nocodazol
microtubul
inhibitor
block
art
delay
wnv
entri
brain
termin
stemloop
flavivir
rna
contain
essenti
cisact
element
play
import
role
viral
replic
interestingli
rang
cellular
protein
identifi
interact
stemloop
flavivir
rna
suggest
potenti
strategi
design
inhibitor
target
host
protein
interact
target
host
factor
may
rais
higher
barrier
viral
resist
emerg
provid
broadspectrum
antivir
effect
howev
current
understand
cell
interact
research
target
host
factor
block
viral
infect
still
limit
addit
potenti
drawback
approach
includ
undesir
druginduc
sideeffect
difficulti
drug
deliveri
brain
control
wnv
enceph
understand
interact
facilit
identif
novel
antivir
agent
develop
test
variou
method
treatment
prevent
wnv
infect
protect
vaccin
therapeut
antibodi
antivir
compound
peptid
sirna
propos
intens
studi
although
number
wnv
veterinari
vaccin
alreadi
licens
use
year
human
vaccin
candid
still
variou
stage
develop
test
therapeut
antibodi
show
excel
efficaci
small
anim
model
current
test
clinic
trial
repres
promis
class
wnv
therapeut
recent
technolog
advanc
increas
understand
biolog
wnv
flavivirus
along
structuralfunct
character
viral
protein
provid
solid
foundat
develop
small
molecul
inhibitor
futur
wnv
therapeut
howev
effort
develop
effect
drug
prevent
control
wnv
infect
human
still
remain
unsuccess
reason
includ
low
incid
diseas
low
commerci
interest
pharmaceut
compani
high
cost
mass
vaccin
difficulti
run
clinic
trial
due
unpredict
sporad
natur
wnv
outbreak
anoth
challeng
develop
success
wnv
therapeut
ensur
safeti
efficaci
target
popul
mostli
includ
children
elderli
immunecompromis
individu
despit
difficulti
quest
develop
effect
treatment
prevent
method
wnv
infect
like
facilit
recent
technolog
advanc
continu
meet
public
health
need
